Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer

  1. Paz-Ares, L.
  2. Socinski, M.A.
  3. Shahidi, J.
  4. Hozak, R.R.
  5. Soldatenkova, V.
  6. Kurek, R.
  7. Varella-Garcia, M.
  8. Thatcher, N.
  9. Hirsch, F.R.
Revista:
Annals of Oncology

ISSN: 1569-8041 0923-7534

Año de publicación: 2016

Volumen: 27

Número: 8

Páginas: 1573-1579

Tipo: Artículo

DOI: 10.1093/ANNONC/MDW214 GOOGLE SCHOLAR lock_openAcceso abierto editor